NGEN

#3659
NervGen Pharma Corp. - Common stock
2.3 2 USD
0.00%
Market Price
Settore: Sconosciuto
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
2.30
2.32
Intervallo Annuale
1.58
6.30
Variazione giornaliera
-0.43%
Variazione Mensile
+42.33%
Variazione di 6 mesi
-41.71%
Variazione Annuale
-63.17%
Chiusura Precedente
2.3 3
Open
2.3 2
Minimo
2.3 0
Massimo
2.3 2
Volume
73
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
NERVGEN PHARMA CORP. current report, Q3 FY2026
6-K
Current report, Q3 FY2026
NERVGEN PHARMA CORP. current report, Q3 FY2026
6-K
Current report, Q2 FY2026
NERVGEN PHARMA CORP. current report, Q2 FY2026
6-K
Current report, Q2 FY2026
NERVGEN PHARMA CORP. current report, Q2 FY2026
6-K
Current report, Q2 FY2026
NERVGEN PHARMA CORP. current report, Q2 FY2026
6-K
Current report, Q2 FY2026
NERVGEN PHARMA CORP. current report, Q2 FY2026
6-K
Current report, Q2 FY2026
NERVGEN PHARMA CORP. current report, Q2 FY2026
6-K
Current report, Q2 FY2026
NERVGEN PHARMA CORP. current report, Q2 FY2026
6-K
Current report, Q1 FY2026
NERVGEN PHARMA CORP. current report, Q1 FY2026
6-K
Current report, Q1 FY2026
NERVGEN PHARMA CORP. current report, Q1 FY2026
6-K

NERVGEN PHARMA CORP. current report, Q2 FY2026

Full document

Business Context and Reporting Period

This Form 6-K filing by NervGen Pharma Corp. covers the month of April 2026, with the report dated April 27, 2026. The filing primarily addresses a material change regarding executive leadership and the results of the Annual Meeting of Shareholders held on April 23, 2026.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and executive compensation rather than financial performance results.

Material Changes

  • Executive Appointment: Dr. Keith Vendola was appointed as Chief Financial Officer, effective April 27, 2026.
  • Compensation Package: Dr. Vendola's annualized base salary is set at $515,000, with eligibility for an annual cash incentive bonus of up to 40% of his base salary.
  • Equity Grant: The Board granted Dr. Vendola stock options to purchase 812,002 common shares at an exercise price of $3.92 per share (based on the April 24, 2026 closing price). The options vest over three years in equal annual installments.
  • Shareholder Actions: Shareholders approved an amendment to the Company's Articles and adopted the NervGen Pharma Corp. 2026 Equity Incentive Plan.

Outlook, Risks, and Contingencies

The filing does not contain specific forward-looking guidance, risk factors, or unusual items beyond the standard disclosure that the employment agreement description is subject to the full text of the agreement. The appointment of a CFO with extensive experience in biotechnology and investment banking suggests a strategic focus on corporate development and financial operations.

Investor Verification Checklist

  • Verify the full terms of the Employment Agreement (Exhibit 10.2) for any additional compensation clauses or termination provisions.
  • Review the details of the 2026 Equity Incentive Plan (Exhibit 10.3) to understand the total pool of shares available for future grants.
  • Confirm the specific nature of the amendment to the Articles of the Company (Exhibit 3.1).
  • Monitor future filings for the first financial report reflecting the new CFO's tenure and strategic impact.